Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Chronic Kidney Disease

Therapeutic area intelligence for Chronic Kidney Disease with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
6
Catalysts
0
Companies
3

Companies

Boehringer Ingelheim →
pharma companies in nephrology →
Renibus Therapeutics →

Assets

Chronic Kidney →
Colchicine →
empagliflozin →
Lactiplantibacillus →
Veverimer →

Recent signals(6)

ClinicalJuly 24, 2026

Study on Thyroid Hormones in Severe CKD Stages G4-G5 Initiated

A retrospective observational study is evaluating thyroid hormone profiles in patients with severe chronic kidney disease, including those with and without Autosomal Dominant Polycystic Kidney Disease.

ClinicalJuly 19, 2026

Renibus Therapeutics initiates long-term study of Veverimer for CKD and metabolic acidosis

Renibus Therapeutics is conducting a 264-week study to assess the efficacy and safety of Veverimer in adults with moderate-to-severe CKD and metabolic acidosis.

ClinicalJuly 15, 2026

Lactiplantibacillus plantarum WJL enhances low-protein diet efficacy in chronic kidney disease

Lactiplantibacillus plantarum WJL supplementation improved metabolic outcomes in CKD patients on a low-protein diet.

ClinicalJuly 11, 2026

Nanotechnology Advances in Podocyte Injury Repair for Chronic Kidney Diseases

Nanotechnology shows promise in repairing podocyte injury, a key factor in chronic kidney diseases, through targeted drug delivery and other mechanisms.

ClinicalJune 25, 2026

Boehringer Ingelheim Tests Vicadrostat with Empagliflozin in CKD Patients

A clinical trial is underway to evaluate the efficacy of vicadrostat combined with empagliflozin in adults with chronic kidney disease.

ClinicalJune 21, 2026

Pilot Trial of Low-Dose Colchicine in CKD Aims to Improve Vascular and Bone Outcomes

A pilot trial is assessing the efficacy of low-dose colchicine in improving vascular disease and biomarkers in CKD stage 3 patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Chronic Kidney Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.